This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
5 Dow Stocks Stand Tall Despite Index's Loss of 2018 Gains
by vidya Nair
The Dow portfolio has depicted weak trends in 2018, thanks to concerns surrounding trade and interest rates. Nevertheless, strong U.S. economic fundamentals are likely to aid revival.
5 Dow Stocks Defying the Index's YTD Plunge
by Nalak Das
The Dow 30 has been witnessing volatility in 2018 so far on account of investors' apprehension regarding investing in risky assets like equities.
Roche to Create Companion Diagnostic Test for Merck's Keytruda
by Zacks Equity Research
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan
by Zacks Equity Research
JP Morgan downgrades Pfizer (PFE) on assumptions that the market has discounted all growth factors for Pfizer.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.42, marking a +0.91% move from the previous day.
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
Mylan Expands Recall of Valsartan to All Unexpired Lots
by Zacks Equity Research
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
Are Options Traders Betting on a Big Move in Merck (MRK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $79.22, moving -0.15% from the previous trading session.
Shire's Takhzyro Gets European Nod for Hereditary Angioedema
by Zacks Equity Research
Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
The Zacks Analyst Blog Highlights: General Motors, Boeing, Microsoft, Merck and UnitedHealth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Motors, Boeing, Microsoft, Merck and UnitedHealth
Novartis' Gilenya Approved in EU for Expanded Population
by Zacks Equity Research
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Key Pharma Players With HIV Focus Ahead of World Aids Day
by Indrajit Bandyopadhyay
We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.
The Zacks Analyst Blog Highlights: Boeing, Merck, Microsoft, UnitedHealth and American Express
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Merck, Microsoft, UnitedHealth and American Express
Bayer (BAYRY) to Restructure Business & Reduce Headcount
by Zacks Equity Research
Bayer (BAYRY) conducts a strategic review of its business model, and plans to exit unprofitable product lines and reduce headcount.
The Zacks Analyst Blog Highlights: Merck, Mastercard, Salesforce, Diageo and State Street
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Mastercard, Salesforce, Diageo and State Street
Dow 30 Stock Roundup: BA's $383M Modification Contract, MSFT's Army Contract
by Swarup Gupta
The Dow recovered from two weeks of losses to post strong gains this week.
Merck (MRK) Receives Approval for 2 HIV Medicines in EU
by Zacks Equity Research
Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.
Dow Records Highest Single Day Gain in 8 Months: 5 Picks
by Nalak Das
Despite stock market mayhem, fundamentals of the U.S. economy remain strong which will help sustain the rally.